Novavax CEO to Present at UBS Global Life Sciences Conference
MALVERN, Pa., Sept. 21 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) -- Novavax, Inc. President and Chief Executive Officer, Dr. Rahul Singhvi, will present at the UBS Global Life Sciences Conference on September 26 at the Grand Hyatt Hotel in New York, the company announced today.
Dr. Singhvi will provide an overview of the company's strategy, research and development progress and strategic partnerships. A link to the webcast of his presentation will be available at 10:30 a.m. on Tuesday, September 26, through the company's website, www.novavax.com. An audio replay will be available beginning approximately three hours after the live presentation.
Novavax Inc. is committed to leading the global fight against infectious disease by creating novel, highly potent vaccines that are safer and more effective than current preventive options. Using the company's proprietary virus-like particle (VLP) and Novasome(R) adjuvant technologies, Novavax is developing vaccines to protect against H5N1 pandemic influenza, seasonal flu and other viral diseases. Novavax's particulate vaccines closely match disease-causing viruses while lacking the genetic material to cause disease, which provides potential for greater immune protection at lower doses than current vaccines. With an exclusive portable manufacturing system that allows for rapid mass-production of vaccines, Novavax is uniquely positioned to meet global public health needs.
SOURCE Novavax, Inc.
CONTACT: Mariann Caprino of Novavax, Inc., +1-484-913-1213